ES2038669T3 - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
ES2038669T3
ES2038669T3 ES198787307973T ES87307973T ES2038669T3 ES 2038669 T3 ES2038669 T3 ES 2038669T3 ES 198787307973 T ES198787307973 T ES 198787307973T ES 87307973 T ES87307973 T ES 87307973T ES 2038669 T3 ES2038669 T3 ES 2038669T3
Authority
ES
Spain
Prior art keywords
units
density
pharmaceutical formulation
baric
liberation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787307973T
Other languages
English (en)
Spanish (es)
Inventor
John Michael Newton
Jane Elizabeth Devereux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London School of Pharmacy Innovations Ltd
Original Assignee
London School of Pharmacy Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868622482A external-priority patent/GB8622482D0/en
Priority claimed from GB878708011A external-priority patent/GB8708011D0/en
Application filed by London School of Pharmacy Innovations Ltd filed Critical London School of Pharmacy Innovations Ltd
Application granted granted Critical
Publication of ES2038669T3 publication Critical patent/ES2038669T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES198787307973T 1986-09-18 1987-09-09 Formulacion farmaceutica. Expired - Lifetime ES2038669T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868622482A GB8622482D0 (en) 1986-09-18 1986-09-18 Pharmaceutical formulation
GB878708011A GB8708011D0 (en) 1987-04-03 1987-04-03 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2038669T3 true ES2038669T3 (es) 1993-08-01

Family

ID=26291305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787307973T Expired - Lifetime ES2038669T3 (es) 1986-09-18 1987-09-09 Formulacion farmaceutica.

Country Status (19)

Country Link
US (1) US4938967A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0265061B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890004686B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE71293T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU606353B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1000616A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1302259C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH674146A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3775880D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK488287A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2038669T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2604090B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2196252B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004268T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU202101B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL83897A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1211484B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ221805A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT85747B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
DK165090D0 (da) * 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
GB9018839D0 (en) * 1990-08-29 1990-10-10 Newton John M Slow release compositions
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
WO1994003184A1 (en) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
ATE186544T1 (de) * 1992-08-04 1999-11-15 James M Dunn Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
FR2703908B1 (fr) * 1993-04-13 1995-06-02 Asta Medica Ag Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs.
US6706188B2 (en) 1993-05-03 2004-03-16 Amersham Biociences Ab Process and means for down stream processing
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
JP2002507399A (ja) * 1998-03-23 2002-03-12 ゼネラル ミルズ インコーポレイテッド 可食性製品への成分のカプセル化
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US20040101540A1 (en) * 1999-09-01 2004-05-27 John Cooker Oral delivery system and method for making same
US20050079214A1 (en) * 1999-09-01 2005-04-14 John Cooker Oral delivery system and method for making same
EP1207852A4 (en) 1999-09-02 2009-11-11 Nostrum Pharmaceuticals Inc ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
ES2287126T3 (es) 2000-04-27 2007-12-16 Verion Inc. Microcapsulas de liberacion de orden cero y controladas por la temperatura y procedimiento para su preparacion.
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US6569808B2 (en) * 2001-07-30 2003-05-27 Lee F. Klinger Methods and compositions useful for bryophyte remediation to improve forest health and growth
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US20070102672A1 (en) * 2004-12-06 2007-05-10 Hamilton Judd D Ceramic radiation shielding material and method of preparation
JPWO2006080481A1 (ja) * 2005-01-31 2008-06-19 杏林製薬株式会社 マルチプルユニット型経口徐放性製剤及びその製造方法
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
US11510894B2 (en) 2006-01-27 2022-11-29 John P. Geibel Fast acting inhibitor of gastric acid secretion
CN103349799B (zh) * 2007-09-07 2016-01-20 马缇医疗股份有限公司 用于持续释放治疗药物的药物核心
EP2317873A4 (en) * 2008-07-22 2015-04-22 Gen Mills Inc FRUIT PRODUCTS CONTAINING OMEGA-3 FATTY ACIDS
US9622972B2 (en) * 2009-03-04 2017-04-18 Emplicure Ab Abuse resistant formula
WO2010128300A1 (en) 2009-05-08 2010-11-11 Aduro Materials Ab Composition for sustained drug delivery comprising geopolymeric binder
AU2010254831B2 (en) * 2009-06-05 2015-11-19 General Mills, Inc. Encapsulated omega-3 fatty acids for baked goods production
CA2809927C (en) 2010-09-07 2019-08-20 Orexo Ab A transdermal drug administration device
US20170172946A1 (en) * 2015-12-21 2017-06-22 Stephan Hau Micro-solid phase extraction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE562124A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1956-11-05
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
CH582002A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-06-09 1976-11-30 Purdue Research Foundation
GB1590574A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1590573A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
GB2015875B (en) * 1978-02-24 1982-10-20 Novex Foreign Trade Co Ltd Solid oral pharaceutical product with increased efficacy and predetermined steady state of solubility
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
RO86519B (ro) * 1979-09-12 1985-03-31 Eli Lilly And Company Dispozitiv pentru rumegatoare
GB2100602B (en) * 1981-06-24 1984-11-14 May & Baker Ltd Device for delivering biologically active substances to the digestive tract.
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
GB2123693B (en) * 1982-07-20 1987-05-13 Nat Res Dev Sustained release device
GB2123690A (en) * 1982-07-20 1984-02-08 Nat Res Dev Sustained release device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
FR2560768A1 (fr) * 1984-03-07 1985-09-13 Crb Virbac Sa Dispositif a liberation programmee
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom

Also Published As

Publication number Publication date
CA1302259C (en) 1992-06-02
IT1211484B (it) 1989-11-03
DE3775880D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-02-20
AU606353B2 (en) 1991-02-07
DK488287D0 (da) 1987-09-17
US4938967A (en) 1990-07-03
IT8767796A0 (it) 1987-09-17
BE1000616A5 (fr) 1989-02-21
GB2196252B (en) 1990-10-17
IL83897A0 (en) 1988-02-29
EP0265061A1 (en) 1988-04-27
FR2604090A1 (fr) 1988-03-25
NZ221805A (en) 1991-02-26
GB2196252A (en) 1988-04-27
KR890004686B1 (ko) 1989-11-25
KR880003617A (ko) 1988-05-28
ATE71293T1 (de) 1992-01-15
HU202101B (en) 1991-02-28
CH674146A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-05-15
HUT45194A (en) 1988-06-28
IL83897A (en) 1991-06-10
EP0265061B1 (en) 1992-01-08
PT85747B (pt) 1991-02-08
DK488287A (da) 1988-03-19
PT85747A (en) 1987-10-01
AU7848187A (en) 1988-03-24
GB8721186D0 (en) 1987-10-14
GR3004268T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-31
FR2604090B1 (fr) 1990-06-15

Similar Documents

Publication Publication Date Title
ES2038669T3 (es) Formulacion farmaceutica.
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
DK0490944T3 (da) Transmucosal doseringsform
DK20488D0 (da) Farmaceutiske praeparater med forlaenget afgivelse
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
NZ514077A (en) Treatment of Α-galactosidase A deficiency
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
Obeid et al. Effect of ibuprofen on the healing and remodeling of bone and articular cartilage in the rabbit temporomandibular joint
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
GR1000989B (el) Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.
KR900013935A (ko) 대머리 환자의 발모촉진용 약제학적 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, s-아데노실메티오닌 및 이들 염의 용도 및 약제학적 조성물
EG17992A (en) Preparation of a medicament for arthritis and theumatism
KR910004190A (ko) 온단세트론의 신규 의학 용도
Shambaugh Jr The diagnosis and treatment of active cochlear otosclerosis1
KR830008678A (ko) 진통 조성물
KR880002521A (ko) 약제 제형
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
BRPI0515833A (pt) oligonucleotìdeos osteogênicos e seus usos
Kuznetsova et al. Benzofurocaine analgesia in acute myocardial infarct
SE8304818L (sv) Medicin med magsarslekande, spasmolytisk och lokalanesteserande verkan
RU97110383A (ru) Способ профилактики и лечения атеросклероза
UA51022A (uk) М'яка желатинова капсула
AR043470A2 (es) Una composicion farmaceutica para ser usada como anticonceptivo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 265061

Country of ref document: ES